CAMX

705.5

-0.56%↓

VITR

143.8

+0.14%↑

EKTA.B

49.12

-0.85%↓

ARJOB

34.16

-2.12%↓

MSON.B

7.9

+1.28%↑

CAMX

705.5

-0.56%↓

VITR

143.8

+0.14%↑

EKTA.B

49.12

-0.85%↓

ARJOB

34.16

-2.12%↓

MSON.B

7.9

+1.28%↑

CAMX

705.5

-0.56%↓

VITR

143.8

+0.14%↑

EKTA.B

49.12

-0.85%↓

ARJOB

34.16

-2.12%↓

MSON.B

7.9

+1.28%↑

CAMX

705.5

-0.56%↓

VITR

143.8

+0.14%↑

EKTA.B

49.12

-0.85%↓

ARJOB

34.16

-2.12%↓

MSON.B

7.9

+1.28%↑

CAMX

705.5

-0.56%↓

VITR

143.8

+0.14%↑

EKTA.B

49.12

-0.85%↓

ARJOB

34.16

-2.12%↓

MSON.B

7.9

+1.28%↑

Search

Vivesto AB

Ouvert

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

2.4M

-8.3M

BPA

-0.015

Employés

4

Dividendes

By Dow Jones

Prochains Résultats

12 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

9.1M

133M

Ouverture précédente

0

Clôture précédente

0

Vivesto AB Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 juil. 2025, 23:57 UTC

Acquisitions, Fusions, Rachats

EQT: To Spend Y407.82B for Tender Offer

29 juil. 2025, 23:56 UTC

Acquisitions, Fusions, Rachats

EQT: Tender Offer Price Is Y5,700 a Share

29 juil. 2025, 23:54 UTC

Acquisitions, Fusions, Rachats

EQT To Start Tender Offer for Fujitec

29 juil. 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 juil. 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 juil. 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 juil. 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 juil. 2025, 22:44 UTC

Acquisitions, Fusions, Rachats

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 juil. 2025, 22:41 UTC

Acquisitions, Fusions, Rachats

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 juil. 2025, 22:41 UTC

Acquisitions, Fusions, Rachats

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 juil. 2025, 22:35 UTC

Résultats

IGO Maintains Nova Life of Mine Production Guidance

29 juil. 2025, 22:35 UTC

Résultats

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 juil. 2025, 22:35 UTC

Résultats

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 juil. 2025, 22:34 UTC

Résultats

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 juil. 2025, 22:34 UTC

Résultats

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 juil. 2025, 22:34 UTC

Market Talk
Résultats

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 juil. 2025, 22:33 UTC

Résultats

IGO Had A$279.7 Million of Cash at End-June

29 juil. 2025, 22:33 UTC

Résultats

IGO 4Q Underlying Free Cash A$2.4 Million

29 juil. 2025, 22:33 UTC

Résultats

IGO FY Sales Revenue A$512.5 Million

29 juil. 2025, 22:33 UTC

Résultats

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 juil. 2025, 22:32 UTC

Résultats

IGO FY Nickel Production 17,173 Tons

29 juil. 2025, 22:32 UTC

Résultats

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 juil. 2025, 22:32 UTC

Résultats

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 juil. 2025, 22:31 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

29 juil. 2025, 22:31 UTC

Market Talk
Résultats

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 juil. 2025, 22:31 UTC

Résultats

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 juil. 2025, 22:31 UTC

Résultats

IGO FY Spodumene Production 1.48 Million Tons

29 juil. 2025, 22:30 UTC

Résultats

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 juil. 2025, 22:30 UTC

Résultats

IGO 4Q Underlying Ebitda A$62 Million

29 juil. 2025, 22:22 UTC

Résultats

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparaison

Variation de prix

Vivesto AB prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.